Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV

Liu, Wang-Da; Pang, Man Wai; Wang, Jann-Tay; Sun, Hsin‐Yun; Huang, Yu‐Shan; Lin, Kuan‐Yin; Wu, Un‐In; Li, Guei-Chi; Liu, Wen-Chun; Su, Yi‐Ching; He, Pu-Chi; Lin, Chia–Yi; Yeh, Chih-Yu; Cheng, Yu‐Chen; Yao, Yi; Chen, Yi-Ting; Wu, Pei‐Ying; Chen, Ling-Ya; Luo, Yi; Chang, Hsi-Yen; Sheng, Wang‐Huei; Hsieh, Shu‐Ching; Chang, Shih‐Ying; Hung, Chien‐Ching; Chang, Shan‐Chwen

doi:10.1016/j.jve.2022.100308

Cited by 3 publications

(1 citation statement)

References 38 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few studies of COVID-19 vaccine responses in PLWH have been conducted with most studies focused on people living in European and North American countries. 4 , 6 , 7 , 8 , 10 , 16 , 17 , 24 , 25 , 26 , 27 We found only one report, a clinical trial conducted in South Africa, from continental Africa. 17 Moreover, the majority of published studies were designed to compare antibody responses following COVID-19 vaccination in people who had not previously had a COVID-19 experience thus allowing a straightforward and uncomplicated analysis.…”

Section: Discussionmentioning

confidence: 88%

Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load

Swan,

Dushimiyimana,

Ndishimye

et al. 2023

iScience

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load

Swan,

Dushimiyimana,

Ndishimye

et al. 2023

iScience

View full text Add to dashboard Cite

Humoral response 24 months after the first COVID-19 vaccination in people with HIV with and without diabetes

Bering,

Heftdal,

Heidari

et al. 2024

Aids

View full text Add to dashboard Cite

People with HIV (PWH) and people with diabetes mellitus have increased risk of severe COVID-19, but little is known about humoral response to COVID-19 vaccines in PWH with DM. We investigated SARS-CoV-2 antireceptor-binding domain (anti-RBD) immunoglobulin G (IgG) geometrical concentrations and neutralizing antibody capacity (nAB) in PWH with and without diabetes mellitus. Anti-RBD IgG and nAB in COVID-19-vaccinated PWH were not associated with diabetes mellitus-status or HbA1c 24 months after the initial COVID-19 vaccination.

show abstract

SARS‐CoV‐2 vaccine immunogenicity for people living with HIV: A systematic review and meta‐analysis

Søndergaard,

Thavarajah,

Churchill Henson

et al. 2023

HIV Medicine

View full text Add to dashboard Cite

BackgroundPrevious publications on the immunogenicity of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines in people living with HIV (PLWH) have reported inconsistent results. Additionally, a meta‐analysis investigating the immunogenicity in PLWH after the third SARS‐CoV‐2 vaccine dose is lacking. In this article we aim to provide a systematic review and a meta‐analysis studying the immunogenicity of SARS‐CoV‐2 vaccines in PLWH and to identify potential drivers for antibody response in PLWH.MethodsWe used three databases (PubMed, Embase and Web of Science) to conduct our review. Studies with information on numbers of PLWH producing immunoglobulin G (IgG) antibodies or neutralizing antibodies were included.ResultsThe meta‐analysis included 59 studies and illustrated a pooled serological response of 87.09% in the 10 343 PLWH after they received a SARS‐CoV‐2 vaccine. High CD4 T‐cell counts and low viral load indicated that the study populations had HIV that was well treated, despite varying in location. The pooled effect increased to 91.62% for 8053 PLWH when excluding studies that used inactivated vaccines (BBIBP‐CorV and CoronaVac). For the third vaccine dose, the pooled effect was 92.35% for 1974 PLWH. Additionally, weighted linear regression models demonstrated weak relationships between CD4 T‐cell count, percentages of people with undetectable HIV load, and age compared with the percentages of PLWH producing a serological response. However, more research is needed to determine the effect of those factors on SARS‐CoV‐2 vaccine immunogenicity in PLWH.ConclusionSARS‐CoV‐2 vaccines show a favourable effect on immunogenicity in PLWH. However, the results are not ideal. This meta‐analysis suggests that a third SARS‐CoV‐2 vaccine dose and good HIV treatment procedures are vital to induce a good immunogenicity in PLWH.

show abstract

Evolution of anti-SARS-CoV-2 spike protein titers after two-dose of COVID-19 vaccination among people living with HIV

Cited by 3 publications

References 38 publications

Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load

Third COVID-19 vaccine dose boosts antibody function in Rwandans with high HIV viral load

Humoral response 24 months after the first COVID-19 vaccination in people with HIV with and without diabetes

SARS‐CoV‐2 vaccine immunogenicity for people living with HIV: A systematic review and meta‐analysis

Contact Info

Product

Resources

About